eBay
EBAY
Ermenegildo Zegna NV
ZGN
Hutchmed (China)
HCM
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -85.12%24.15M | -14.26%1.09B | -6.31%537.61M | -39.99%164.19M | -8.94%224.76M | -7.64%162.31M | 15.59%1.27B | 3.77%573.83M | 227.70%273.61M | -16.64%246.83M |
Net income from continuing operations | -63.45%21.85M | -1.82%355.54M | -11.10%105.8M | -8.06%122.69M | 4.37%67.26M | 32.20%59.79M | -52.79%362.13M | -27.38%119.01M | -56.45%133.45M | -48.64%64.44M |
Operating gains losses | ---- | -80.82%-3.98M | ---- | ---- | ---- | ---- | 21.62%-2.2M | ---- | ---- | ---- |
Depreciation and amortization | 6.14%153.82M | -5.83%594.66M | -6.23%149.19M | -4.53%150.6M | -5.03%149.95M | -7.55%144.93M | 3.07%631.51M | 1.33%159.11M | 0.90%157.75M | 4.46%157.89M |
Deferred tax | ---- | -105.85%-784K | ---- | ---- | ---- | ---- | 215.24%13.39M | ---- | ---- | ---- |
Other non cash items | -57.68%5.97M | -42.06%11.69M | -3.13%-10.86M | -82.29%4.59M | -49.17%3.87M | 599.82%14.1M | 1,464.57%20.18M | -148.58%-10.53M | 350.44%25.93M | 136.04%7.61M |
Change In working capital | -178.75%-157.49M | -52.11%113.37M | -2.41%279.87M | -161.20%-113.69M | -78.20%3.68M | -141.25%-56.5M | 184.12%236.73M | 35.74%286.77M | 88.20%-43.52M | -58.35%16.9M |
-Change in receivables | ---- | -51.49%99.69M | ---- | ---- | ---- | ---- | 297.61%205.49M | ---- | ---- | ---- |
-Change in inventory | ---- | -66.22%78.97M | ---- | ---- | ---- | ---- | 257.82%233.8M | ---- | ---- | ---- |
-Change in payables and accrued expense | ---- | 82.33%-32.34M | ---- | ---- | ---- | ---- | -498.39%-183.01M | ---- | ---- | ---- |
-Change in other current assets | ---- | -84.45%9.98M | ---- | ---- | ---- | ---- | 187.80%64.2M | ---- | ---- | ---- |
-Change in other current liabilities | ---- | 56.09%-36.4M | ---- | ---- | ---- | ---- | -1,081.51%-82.91M | ---- | ---- | ---- |
-Change in other working capital | ---- | -673.34%-6.53M | ---- | ---- | ---- | ---- | 92.00%-844K | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -85.12%24.15M | -14.26%1.09B | -6.31%537.61M | -39.99%164.19M | -8.94%224.76M | -7.64%162.31M | 15.59%1.27B | 3.77%573.83M | 227.70%273.61M | -16.64%246.83M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 26.77%-63.05M | 15.92%-800.32M | -17.08%-298.57M | 18.46%-226.69M | 28.20%-188.96M | 44.70%-86.1M | 5.49%-951.91M | 10.19%-255.01M | -41.46%-278.03M | 8.20%-263.17M |
Net PPE purchase and sale | 18.38%-75.69M | 0.16%-739.82M | -24.20%-286.85M | 14.69%-195.24M | 10.15%-165M | 4.96%-92.73M | 18.13%-741.02M | 30.51%-230.95M | 1.93%-228.87M | -1.06%-183.63M |
Net investment purchase and sale | 434.68%11.13M | 67.24%-70.69M | 39.81%-14.48M | 31.82%-33.53M | 70.60%-24.77M | 103.57%2.08M | -105.43%-215.77M | -150.52%-24.05M | -237.10%-49.18M | 20.37%-84.24M |
Net other investing changes | -66.95%1.5M | 108.50%10.18M | 25,100.00%2.75M | 8,208.00%2.08M | -82.81%809K | 2,671.34%4.55M | 62.28%4.88M | -101.43%-11K | -97.40%25K | 473.08%4.71M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 26.77%-63.05M | 15.92%-800.32M | -17.08%-298.57M | 18.46%-226.69M | 28.20%-188.96M | 44.70%-86.1M | 5.49%-951.91M | 10.19%-255.01M | -41.46%-278.03M | 8.20%-263.17M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 39.54%-42.25M | -74.54%-260.43M | -196.19%-53.1M | -9.90%-68.85M | 9.20%-68.6M | -5.54%-69.88M | -368.37%-149.21M | 12.99%55.2M | -646.41%-62.65M | 33.70%-75.55M |
Net issuance payments of debt | 16.77%-41.15M | -12.89%-81.54M | -8.84%68.42M | -13.76%-50.04M | 12.02%-50.47M | -7.65%-49.44M | -163.39%-72.23M | 13.16%75.06M | -293.08%-43.99M | 40.22%-57.37M |
Cash dividends paid | --0 | -139.14%-178.61M | -522.01%-120.41M | -5.22%-19.42M | -5.16%-19.4M | -5.17%-19.38M | -35.51%-74.69M | -5.26%-19.36M | -50.62%-18.45M | -50.62%-18.44M |
Proceeds from stock option exercised by employees | ---- | 40.23%5M | ---- | ---- | ---- | ---- | -36.79%3.56M | ---- | ---- | ---- |
Net other financing activities | -4.37%-1.1M | 9.77%-5.29M | -50.49%-6.1M | 384.43%603K | 386.21%1.27M | 43.08%-1.05M | 33.96%-5.86M | 14.01%-4.06M | -122.63%-212K | 104.55%261K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 39.54%-42.25M | -74.54%-260.43M | -196.19%-53.1M | -9.90%-68.85M | 9.20%-68.6M | -5.54%-69.88M | -368.37%-149.21M | 12.99%55.2M | -646.41%-62.65M | 33.70%-75.55M |
Net cash flow | ||||||||||
Beginning cash position | 1.22%1.13B | 16.44%1.12B | 29.78%959.93M | 33.67%1.08B | 22.50%1.12B | 16.44%1.12B | 15.74%962.41M | 17.91%739.68M | 9.61%808.26M | 6.30%913.3M |
Current changes in cash | -1,381.68%-81.16M | -83.36%28.11M | -50.29%185.94M | -95.86%-131.36M | 64.30%-32.8M | 113.72%6.33M | 14.76%168.9M | 17.66%374.02M | 33.98%-67.07M | 12.10%-91.89M |
Effect of exchange rate changes | 163.35%5.17M | -34.84%-14.42M | -267.11%-11.55M | 817.99%10.86M | 57.71%-5.56M | -177.40%-8.16M | 34.40%-10.69M | -59.80%6.91M | 82.15%-1.51M | 23.67%-13.15M |
End cash Position | -5.40%1.06B | 1.22%1.13B | 1.22%1.13B | 29.78%959.93M | 33.67%1.08B | 22.50%1.12B | 16.44%1.12B | 16.44%1.12B | 17.91%739.68M | 9.61%808.26M |
Free cash flow | -184.28%-55.75M | -33.71%345.07M | -25.04%251.88M | -170.78%-31.33M | -6.96%58.38M | -14.68%66.14M | 173.31%520.55M | 52.60%336.02M | 129.16%44.26M | -44.98%62.75M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |